Ardelyx Inc ARDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ARDX is a good fit for your portfolio.
News
-
Thinking about buying stock in Intuitive Machines, OPKO Health, Ardelyx, AXT Inc, or Clearmind Medicine?
-
Thinking about buying stock in Macy's, Ardelyx, SoFi Technologies, Panbela Therapeutics, or Himax Technologies?
-
Ardelyx Shares Rally Premarket on FDA Approval of Xphozah
-
Ardelyx Gets FDA OK for Add-On Therapy for Kidney Disease Patients
-
Ardelyx wins long battle for FDA approval of kidney-disease treatment
-
Ardelyx shares climb as kidney-disease drug gets green light from Japanese regulators
Trading Information
- Previous Close Price
- $6.31
- Day Range
- $6.30–6.59
- 52-Week Range
- $3.16–10.13
- Bid/Ask
- $6.43 / $6.46
- Market Cap
- $1.49 Bil
- Volume/Avg
- 5.5 Mil / 5.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.31
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 267
- Website
- https://www.ardelyx.com
Comparables
Valuation
|
Metric
|
ARDX
|
ITCI
|
ALDX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 8.95 | 11.92 | 1.94 |
Price/Sales | 11.31 | 15.17 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ARDX
ITCI
ALDX
Financial Strength
|
Metric
|
ARDX
|
ITCI
|
ALDX
|
|---|---|---|---|
Quick Ratio | 4.09 | 4.95 | 6.42 |
Current Ratio | 4.88 | 5.41 | 6.64 |
Interest Coverage | −6.38 | — | −20.66 |
Quick Ratio
ARDX
ITCI
ALDX
Profitability
|
Metric
|
ARDX
|
ITCI
|
ALDX
|
|---|---|---|---|
Return on Assets (Normalized) | −22.97% | −13.47% | −19.85% |
Return on Equity (Normalized) | −39.28% | −15.88% | −24.05% |
Return on Invested Capital (Normalized) | −26.80% | −17.96% | −24.99% |
Return on Assets
ARDX
ITCI
ALDX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mddgqfjynb | Rpyv | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jrkndlwl | Spmcwh | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cjcbrdk | Pmtbht | $97.8 Bil | |
MRNA
| Moderna Inc | Qbykrdcfk | Jwvfm | $41.3 Bil | |
ARGX
| argenx SE ADR | Zkmkwtw | Rdtt | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Dnpxbjjvh | Gkht | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jprrxhwqd | Vghdp | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Whplpysy | Vvnkwh | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Khvbkgkgp | Pthwbx | $12.5 Bil | |
INCY
| Incyte Corp | Vhtfnmgz | Bzwbgq | $11.6 Bil |